Baden-Württembergisches Brasilien- und Lateinamerika-Zentrum

01.09.2021

Discovery of Plasmodium falciparum Inhibitors as Lead Candidates for Malaria: Structural Biology and Medicinal Chemistry Studies

das Brasilien-Zentrum der Universität Tübingen lädt Sie zum  „Discovery of Plasmodium falciparum Inhibitors as Lead Candidates for Malaria: Structural Biology and Medicinal Chemistry Studies“ mit Prof. Dr. Rafael V. C. Guido von University of São Paulo (IFSC/USP) ein.

Malaria is one of the most prevalent parasitic infection in the world. In 2019, the disease affected 229 million people and killed over 409,000 people. Therefore, new molecular targets and drug candidates are extremely needed. In this seminar, two strategies towards the discovery of new Plasmodium falciparum inhibitors will be presented. The first approach relied on the investigation of a glycolytic enzyme that plays important roles in Plasmodium biology. Enolase (EC 4.2.1.11) catalyses the reversible interconversion of 2-phosphoglyceric acid to phosphoenolpyruvic acid. In this study, we report the discovery of “ENOblock”, a non-competitive P. falciparum enolase inhibitor, with inhibitory activity in the submicromolar range. Moreover, we solved the 3D structure of the Enolase-ENOblock complex and demonstrated that the compound inhibits the in vitro growth of the parasite (sensitive and resistant strains). In vivo studies showed that the compound was well tolerated and significantly reduced the parasitemia. Our findings indicate that enolase can be explored as molecular target for the design of new lead compounds. In another work, a comprehensive study including synthesis, SAR, and parasitological profiling was conducted to discover marinoquinoline derivatives as a new class of P. falciparum inhibitors. The most promising compounds of this series showed inhibitory activity in the low nanomolar range, fast-acting inhibitory activity with noticeable activity in the early stage of intraerythrocytic cycle and liver stages of development. A representative compound showed an excellent tolerability in non-infected mice and reasonable oral efficacy in the P. berghei malaria mouse model.


Mittwoch, 08. September 2021, 3 PM Brasilien - 8 PM Deutschland, ein.
Veranstaltung auf Englisch.
Bei Interesse bitten wir um Anmeldung bis Dienstag, den 07. September 2021,   zoom.us/meeting/register/tJcpf--hpjwjEtbFH5jgyhygd60cVuf2FVFi

Nach Ihrer Anmeldung erhalten Sie weitere Informationen zum Zoom-Zugang und zum technischen Ablauf.

Zurück